Hematopoietic stem cell gene therapy for the treatment of β-hemoglobinopathies
Hematopoietic stem cell gene therapy with CRISPR/Cas9 mRNA and AAV6 vector in metachromatic leukodystrophy
Development of novel mRNA-based therapy strategies targeting rhabdoid tumors
CRISPR/Cas9-boosted improvements in CAR-T and CAR-NK cell-based immunotherapy for cancer treatment
Lipid nanoparticles (LNPs) for ex vivo editing of hematopoietic stem cells and immune effector cells
frontend.sr-only_#{element.icon}: Prof. Dr. med. Dr. rer. nat. Dipl. Biol. Markus Mezger Group leader
E-mail address: markus.mezger@med.uni-tuebingen.de
frontend.sr-only_#{element.icon}:
Dr. rer. nat. Justin Selvaraj
Associated advisor
E-mail address: justin.selvaraj@med.uni-tuebingen.de
frontend.sr-only_#{element.icon}: Dr. Tahereh Mohammadian Gol Postdoc
E-mail address: Tahereh.Mohammadian-Gol@med.uni-tuebingen.de
Our team is primarily working in the field of hematopoietic stem cell transplanation (HSCT). By utilizing various cell and gene therapy approaches, we aim to develop novel gene therapy modalities for β- hemoglobinopathies (β-thalassemia, sickle cell disease), cancer immunotherapy, and rare diseases including metachromatic leukodystrophy and immunodeficiency. Our technologies include lentiviral (LV) and Adeno-associated virus (AAV) gene transfer, mRNA therapeutics, adoptive immune cell therapy, genome editing and gene correction using CRISPR / Cas9 system.
(Lamsfus Calle et al., 2019, Blood Reviews, https://doi.org/10.1016/j.blre.2019.100641)
(Ureña Bailén et al., 2019, Briefings in Functional Genomics, https://doi.org/10.1093/bfgp/elz039)
(Daniel Moreno et al., 2019, Bone Marrow Transplantation, https://doi.org/10.1038/s41409-019-0510-8)
As we focus on HSCT, in our research we are addressing a major adverse effect called graft versus host disease (GvHD), a serious complication after allogeneic stem cell transplantation. To achieve this goal, we are utilizing donor’s immune cells including mesenchymal stromal cells, myeloid suppressor cells and regulatory T cells to better control immune reaction of the graft through immune modulation.
We are employing state-of-the-art technologies including sequencing, fragment analysis, droplet digital PCR (ddPCR) and developing innovative methods in order to identify optimized stem cell donors, and improving previous diagnostic routine assays for chimerism analysis, KIR genotyping and minimal residual disease (MRD) analysis.
Fortüne Programm Tübingen
Clinician Scientist Programm Tübingen
IZKF Tübingen
José Carreras Leukämie-Stiftung e. V.
Förderverein für krebskranke Kinder Tübingen e.V.
Stiftung des Fördervereins krebskranke Kinder Tübingen
Manchot Stiftung
DEBRA Austria
Bundesministerium für Bildung und Forschung
Deutsches Zentrum für Infektionsforschung
Stefan-Morsch Stiftung
Madeleine Schickedanz Stiftung
* These authors contributed equally to this work, respectively.
